These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 25087600)

  • 1. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP; Loft H; Olsen CK
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
    J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
    François C; Nielsen R; Danchenko N; Williams V; Lançon C
    Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A; Florea I; Loft H; Christensen MC
    J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A; Fagiolini A; Maina G
    Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
    McIntyre RS; Florea I; Pedersen MM; Christensen MC
    J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.